Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Zaiqi Wang"'
Autor:
Baoyuan Zhang, Ning Li, Jiaming Gao, Yuxi Zhao, Jun Jiang, Shuang Xie, Cuiping Zhang, Qingyu Zhang, Leo Liu, Zaiqi Wang, Dongmei Ji, Lingying Wu, Ruibao Ren
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-21 (2024)
Abstract Backgrounds Immune checkpoint blockade (ICB) is widely considered to exert long-term treatment benefits by activating antitumor immunity. However, many cancer patients show poor clinical responses to ICB due in part to the lack of an immunog
Externí odkaz:
https://doaj.org/article/f6130e669747441399b8af4774e9863a
Autor:
Ximin Tan, Deguang Kong, Zhuoli Tao, Fangling Cheng, Baoyuan Zhang, Zaiqi Wang, Qi Mei, Chuang Chen, Kongming Wu
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-24 (2024)
Abstract Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype lacking effective targeted therapies, necessitating innovative treatment approaches. While targeting ROS proto-oncogene 1 (ROS1) with crizotinib has shown
Externí odkaz:
https://doaj.org/article/24d48c60eaca471d9e58400153b83d6a
Autor:
Meng Qiao, Fei Zhou, Xinyu Liu, Tao Jiang, Haowei Wang, Xuefei Li, Chao Zhao, Lei Cheng, Xiaoxia Chen, Shengxiang Ren, Zaiqi Wang, Caicun Zhou
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-20 (2024)
Abstract Background KRAS mutation is one of the most common oncogenic drivers in NSCLC, however, the response to immunotherapy is heterogeneous owing to the distinct co-occurring genomic alterations. KRAS/LKB1 co-mutated lung adenocarcinoma displays
Externí odkaz:
https://doaj.org/article/c7b5672223364226bbaa66549a19fe3f
Autor:
Baoyuan Zhang, Ning Li, Jiaming Gao, Yuxi Zhao, Jun Jiang, Shuang Xie, Cuiping Zhang, Qingyu Zhang, Leo Liu, Zaiqi Wang, Dongmei Ji, Lingying Wu, Ruibao Ren
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/271b108b001b4fa19b7c384d303290b8
Autor:
Arsen Osipov, Alex B. Blair, Juliane Liberto, Jianxin Wang, Keyu Li, Brian Herbst, Yao Xu, Shiqi Li, Nan Niu, Rufiaat Rashid, Ding Ding, Yanan Liu, Zaiqi Wang, Christopher L. Wolfgang, Richard A. Burkhart, Daniel Laheru, Lei Zheng
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 1, Pp 206-214 (2021)
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, due in large part to its resistance to conventional therapies, including radiotherapy (RT). Despite RT exerting a modest antitumor response, it has also been shown to promote
Externí odkaz:
https://doaj.org/article/39e6bd391a9843878fe8179f827b11f3
Publikováno v:
Advanced Science, Vol 8, Iss 16, Pp n/a-n/a (2021)
Abstract KRAS mutation is one of the most prevalent genetic drivers of cancer development, yet KRAS mutations are until very recently considered undruggable. There are ongoing trials of drugs that target the KRAS G12C mutation, yet acquired drug resi
Externí odkaz:
https://doaj.org/article/a31d96a1af6c4b72ab49e6db22443a6f
Autor:
Zaiqi Wang, Guojun Shang, Dong Dinh, Shan Yan, Jin Luo, Aimin Huang, Lefu Yang, Susan Lu, Chuan-Jian Zhong
Publikováno v:
Sensors, Vol 22, Iss 7, p 2781 (2022)
This paper describes the design of a low-current, multichannel, handheld electronic device integrated with nanostructured chemiresistor sensor arrays. A key design feature of the electronic circuit board is its low excitation current for achieving op
Externí odkaz:
https://doaj.org/article/d4889d2aaa774943bc54758eb28c4d18
Autor:
Jiaming Gao, Yunying Yao, Chenxuan Liu, Xi Xie, Donghe Li, Ping Liu, Zaiqi Wang, Baoyuan Zhang, Ruibao Ren
Publikováno v:
International Journal of Biological Sciences. 19:2711-2724
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::835d03a271b197ef15a81937aa9d9879
https://doi.org/10.7150/ijbs.81918
https://doi.org/10.7150/ijbs.81918
Autor:
Baoyuan Zhang, Ning Li, Jiaming Gao, Yuxi Zhao, Jun Jiang, Shuang Xie, Cuiping Zhang, Qingyu Zhang, Leo Liu, Zaiqi Wang, Dongmei Ji, Linying Wu, Ruibao Ren
Immune checkpoint blockade (ICB) is widely considered to exert long-term treatment benefits by activating antitumor immunity. However, many cancer patients show poor clinical responses to ICB due in part to the lack of immunogenic niche. Focal adhesi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f614183eb27e194c078fe5c357444c8c
https://doi.org/10.21203/rs.3.rs-2639424/v1
https://doi.org/10.21203/rs.3.rs-2639424/v1
Autor:
Meng Qiao, Fei Zhou, Xinyu Liu, Tao Jiang, Haowei Wang, Xuefei Li, Chao Zhao, Lei Cheng, Xiaoxia Chen, Shengxiang Ren, Zaiqi Wang, Caicun Zhou
Background KRAS mutation is one of the most common oncogenic drivers in NSCLC, however, the response to immunotherapy is heterogeneous owing to the distinct co-occurring genomic alterations. KRAS/LKB1 co-mutated lung adenocarcinoma displays poor resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc9aebb4d18c22f865a94c5a5c58b234
https://doi.org/10.21203/rs.3.rs-2283207/v1
https://doi.org/10.21203/rs.3.rs-2283207/v1